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background: Sporadic anovulation among regularly menstruating women is not well understood. It is hypothesized that cholesterol
abnormalities may lead to hormone imbalances and incident anovulation. The objective was to evaluate the association between lipoprotein
cholesterol levels and endocrine and metabolic disturbances and incident anovulation among ovulatory and anovulatory women reporting
regular menstruation.
methods: The BioCycle Study was a prospective cohort study conducted at the University at Buffalo from September 2005 to 2007,
which followed 259 self-reported regularly menstruating women aged 18–44 years, for one or two complete menstrual cycles. Sporadic
anovulation was assessed across two menstrual cycles.
results: Mean total and low-density lipoprotein cholesterol and triglycerides levels across the menstrual cycles were higher during ano-
vulatory cycles (mean difference: 4.6 (P ¼ 0.01), 3.0 (P ¼ 0.06) and 6.4 (P ¼ 0.0002) mg/dl, respectively, adjusted for age and BMI). When
multiple total cholesterol (TC) measures prior to expected ovulation were considered, we observed a slight increased risk of anovulation
associated with increased levels of TC (odds ratio per 5 mg/dl increase, 1.07; 95% confidence interval, 0.99, 1.16). Sporadic anovulation
was associated with an increased LH:FSH ratio (P ¼ 0.002), current acne (P ¼ 0.02) and decreased sex hormone-binding globulin levels
(P ¼ 0.005).
conclusions: These results do not support a strong association between lipoprotein cholesterol levels and sporadic anovulation.
However, sporadic anovulation among regularly menstruating women is associated with endocrine disturbances which are typically observed
in women with polycystic ovary syndrome.
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Introduction
Ovulatory disorders are one of the leading causes of female infertility,
affecting between 18 and 30% of infertile couples (Hull et al., 1985;
Smith et al., 2003). Sporadic anovulatory cycles may occur among reg-
ularly menstruating women; however, the prevalence of eumenorrheic
anovulation has not been well described (Malcolm and Cumming,
2003; Barbieri, 2004). Ovulation is the product of the intricate regu-
lation of the hypothalamic–pituitary–ovarian axis by reproductive
hormones. Reproductive hormones are derived from cholesterol;
therefore, lipoprotein cholesterol abnormalities may lead to aberrant
hormone production and anovulation, the so-called steroid hypothesis
(Strauss, 2004).
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There is some evidence of a more atherogenic lipid profile
[increased levels of total cholesterol (TC), low-density lipoprotein
(LDL) cholesterol and triglycerides, and decreased levels of high-
density lipoprotein (HDL) cholesterol] among women with certain
ovulatory disorders, specifically among women with polycystic ovary
syndrome (PCOS) (Essah et al., 2007). In addition to anovulation
(usually observed as irregular menstrual cycles), women with PCOS
also display signs of androgen excess. Common endocrine abnormal-
ities observed in women with PCOS include insulin resistance and
elevated LH:FSH ratio (Azziz et al., 2009). It is possible that anovula-
tion among regularly menstruating women may be associated with
endocrine changes similar to those seen in women with PCOS.
The objective of this study was to (i) prospectively evaluate the
relationship between serum lipoprotein cholesterol levels and incident
anovulation among a group of regularly menstruating women and
(ii) compare endocrine and metabolic parameters in ovulatory and
anovulatory women with regular menstruation.
Materials and Methods
Study sample
The BioCycle Study was a prospective cohort of 259 women followed for
one (n ¼ 9) or two (n ¼ 250) menstrual cycles (Wactawski-Wende et al.,
2009). Participants were recruited from healthy premenopausal volunteers
aged 18–44 years from the western New York region. Women were
included if they had a self-reported cycle length between 21 and 35 days
for each menstrual cycle during the past 6 months. Exclusion criteria
included a history of gynecological problems, endometriosis or self-
reported diagnosis of PCOS by a physician, use of oral contraceptives
during the past 3 months, use of other medications including lipid-lowering
drugs, pregnancy in the last 6 months, chronic disease or a self-reported BMI
at screening ,18 or .35 kg/m2. Full detail on inclusion and exclusion cri-
teria have been reported elsewhere (Wactawski-Wende et al., 2009). The
University at Buffalo Health Sciences Institutional Review Board approved
the study, and all participants provided written informed consent. Under
a reliance agreement, the National Institutes of Health depends on the
designated IRB of the University at Buffalo for review, approval, and conti-
nuing oversight of its human subject research for the BioCycle Study.
Data collection
The study involved five to eight clinical visits per cycle (94% of all women com-
pleted at least seven visits per cycle) for up to two cycles. Visits were timed
using fertility monitors (Clearbluew Easy Fertility Monitor, Inverness Medical,
Waltham, MA, USA) so that biospecimen collection occurred during specific
phases of the cycle, inclusive of peri-ovulation (Howards et al., 2009). Moni-
tors measured estrone-3-glucuronide and LH in urine daily, starting on the
sixth day following the start of the woman’s menstrual cycle. Monitor indi-
cations of low, high and peak fertility were used to time mid-cycle visits.
Other visits were then scheduled accordingly based on an algorithm that
took each woman’s self-reported cycle length into consideration.
Lipoprotein assessment
A complete lipid profile was performed for each participant from fasting
serum samples collected at each clinic visit (Browne et al., 2008). The
lipid profile included analysis of TC, HDL and triglycerides, measured
using a Beckman LX20 automated chemistry analyzer. LDL was deter-
mined indirectly using the Friedewald formula (Friedewald et al., 1972).
Across the study period, the coefficient of variation
(CV) was ,5% for all lipid and lipoprotein assays. Baseline levels were
assessed on the second day of menses during the first cycle.
Endocrine and metabolic assessment
LH, FSH, sex hormone-binding globulin (SHBG) and insulin were
measured in fasting serum samples, using a solid-phase competitive
chemiluminescent enzymatic immunoassay (Specialty Laboratories, Inc.,
Valencia, CA, USA) on the DPC Immulitew2000 analyzer (Siemens
Medical Solutions Diagnostics, Deerfield, IL, USA). Fasting plasma
glucose was assayed using a hexokinase-based methodology on a
Beckman LX20 autoanalyzer. The CVs were ,5% for LH and FSH,
,3% for glucose and ,10% for SHBG and insulin. Insulin resistance, as
measured by the homeostasis model assessment of insulin resistance
(HOMA-IR), was calculated based on the homeostasis model using the
equation: fasting insulin (mU/ml) × fasting glucose (mmol/l)/22.5
(Matthews et al., 1985). Hirsutism was assessed at baseline via a body
hair patterns questionnaire (a modification of the Ferriman–Gallwey
hirsutism score) (Ferriman and Gallwey, 1961) and prevalence of
current acne was assessed at baseline via questionnaire.
Classification of anovulation
Progesterone levels were measured in fasting serum samples collected at
each clinical visit, using a solid-phase competitive chemiluminescent enzy-
matic immunoassay (Specialty Laboratories, Inc.) on the DPC Immuli-
tew2000 analyzer (Siemens Medical Solutions Diagnostics) (CV , 14%).
Menstrual cycles were classified as anovulatory if the peak progesterone
concentration across the cycle was ≤5 ng/ml (n ¼ 65, 13%) (Abdulla
et al., 1983; Malcolm and Cumming, 2003). We also employed a more
conservative classification of ovulation to minimize potential misclassifi-
cation, in which cycles with progesterone concentrations ≤5 ng/ml, but
with an observed serum LH peak on the mid- or late-luteal phase visit,
were considered ovulatory (Gaskins et al., 2009). On the basis of the con-
servative approach, 42 of the 509 cycles (8.3%) in this study were classified
as anovulatory. Overall, 35 (13.5%) women had at least one anovulatory
cycle, 28 (10.8%) women had one anovulatory cycle and 7 (2.7%)
women had two anovulatory cycles.
Covariate assessment
Participants were asked to complete questionnaires on demographics, life-
style (smoking status), physical activity (Craig et al., 2003) and reproduc-
tive history. Physical and anthropometric measures were performed
according to standardized protocols and included height, weight and
waist and hip circumference (Lohman et al., 1988). Dietary intake was
assessed up to four times per cycle by 24-h recall (University of Minnesota,
Minneapolis, MN, USA), and used to calculate the average total fiber and
energy intake across each cycle. Cycle length was defined as the number of
days from the first day of bleeding until the day before the next onset of
bleeding.
Statistical analysis
Descriptive statistics were computed for all study variables and compared
between ovulatory women and women with at least one anovulatory
cycle, using analysis of variance to test for differences in means and x2
tests for differences in categorical variables. Mean baseline lipoprotein
cholesterol levels, and levels across the cycle, were compared between
ovulatory and anovulatory women, adjusted for age and BMI. Linear
mixed models were used to calculate the predicted mean values and
95% confidence intervals (CIs) of age- and BMI-adjusted lipoprotein
cholesterol levels and other endocrine markers. Geometric means are
presented for non-normally distributed variables.
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Generalized linear-mixed models with random intercepts were used to
model the association between baseline lipoprotein cholesterol levels (TC,
HDL, LDL and triglycerides) and the probability of incident anovulation
across two cycles (Diggle et al., 2002). Odds ratios (ORs) and CIs were
calculated to represent a 5-mg/dl change in lipoprotein levels adjusted
for age, age at menarche, BMI, average fiber intake and average total
energy intake. We compared the results after additional adjustment for
the LH:FSH ratio, HOMA-IR, insulin, SHBG, hirsutism score and current
acne, to determine whether associations between baseline lipoprotein
cholesterol levels and anovulation could be related to underlying endo-
crine disturbances. To investigate these associations further, we evaluated
whether these endocrine parameters themselves were significant predic-
tors of sporadic anovulation when adjusting for lipoprotein cholesterol
levels. We additionally assessed the impact of including multiple lipopro-
tein cholesterol measurements up to the time of expected ovulation (up
to four per woman) to increase our statistical power to detect effects.
Stabilized inverse probability weights were used to adjust for time-
dependent confounding owing to changing hormone levels across the
cycle (Robins et al., 2000; Cole and Hernan, 2008). Statistical significance
was defined as P , 0.05 for a two-tailed test. SAS version 9.1 (SAS Insti-
tute, Cary, NC, USA) was used for all statistical analyses.
Results
Women in the BioCycle Study were on average 27.3 years of age
(range 18–44) and consisted mainly of single, nulliparous, normal
weight, and white women with some post-secondary education.
Women with at least one anovulatory cycle (13.5%) were on
average younger, single, nulliparous and with fewer years since
menarche (Table I). Neither age at menarche (P ¼ 0.37), BMI (P ¼
0.25) or waist-to-hip ratio (P ¼ 0.79) differed between women with
ovulatory and anovulatory cycles.
.............................................................................................................................................................................................
Table I Baseline demographic characteristics and lipoprotein cholesterol levels of women, by ovulatory status.
Overall Ovulatory Anovulatorya P-valueb
n 5 259 n 5 224 n 5 35
Demographics
Age, years: mean+ SD 27.3+8.2 28.0+8.3 22.5+5.6 ,0.01
BMI, kg/m2: mean+ SD 24.1+3.9 24.2+3.9 23.4+3.8 0.25
Waist-to-hip ratio: mean+ SD 0.75+0.05 0.75+0.06 0.76+0.03 0.79
Cycle 1 length, days: mean+ SD 28.9+4.6 29.0+4.5 28.7+5.3 0.73
Cycle 2 length, days: mean+ SD 28.7+3.5 28.8+3.2 28.2+5.3 0.47
Physical activity: n (%) 0.86
Low 25 (9.7) 22 (9.8) 3 (8.6)
Moderate 92 (35.5) 81 (36.2) 11 (31.4)
High 142 (54.8) 121 (54.0) 21 (60.0)
Race: n (%) 0.85
White 154 (59.5) 134 (59.8) 20 (57.1)
Black 51 (19.7) 43 (19.2) 8 (22.9)
Other 54 (20.9) 47 (21.0) 7 (20.0)
≤High school education: n (%) 33 (12.7) 29 (13.0) 4 (11.4) 1.00
Current smoker: n (%) 10 (3.9) 9 (4.0) 1 (2.9) 1.00
Married: n (%) 66 (25.5) 65 (29.0) 1 (2.9) ,0.01
Nulliparous: n (%) 187 (73.9) 154 (70.0) 33 (100.0) ,0.01
Past OC use: n (%) 140 (54.9) 127 (57.2) 13 (39.4) 0.06
Age at menarche, years: mean+ SD 12.5+1.2 12.4+1.2 12.6+1.4 0.37
Years since menarche: mean+ SD 14.9+8.3 15.7+8.3 9.6+6.4 ,0.01
Total energy intake, kcals: mean+ SD 1603.5+397.7 1597.5+397.0 1641.5+405.8 0.54
Total fiber intake, g/day: mean+ SD 13.6+6.0 13.4+5.7 15.1+7.1 0.11
Baseline lipoprotein cholesterol levels (mg/dl)c
TC: mean+ SD 163.4+29.0 162.8+1.9 167.3+4.9 0.39
HDL cholesterol: mean+ SD 50.1+11.5 50.0+0.8 50.6+2.0 0.79
LDL cholesterol: mean+ SD 101.5+25.7 101.1+1.7 104.0+4.3 0.54
Triglycerides: mean+ SD 59.2+27.9 58.5+1.8 64.0+4.7 0.28
ANOVA, analysis of variance; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; OC, oral contraceptives; TC, total cholesterol.
aAt least one anovulatory cycle. Twenty-eight women in the study had only one anovulatory cycle, and seven women in the study had two anovulatory cycles. There were a total of 42
anovulatory cycles out of a total 509 in the BioCycle Study.
bP-value for continuous variables calculated using ANOVA, and for categorical variables using Fisher’s exact test.
cBaseline levels were measured at the first visit of the first cycle. Values for ovulatory and anovulatory cycles are predicted means after adjusting for age and BMI.
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After adjustment for age and BMI, we observed that ovulatory
women had lower baseline TC, LDL and triglyceride levels than ano-
vulatory women, although these differences were not statistically sig-
nificant (Table I). However, when we considered multiple
measurements across the cycle, we detected higher levels of TC
(mean difference 4.6 mg/dl, P ¼ 0.01), LDL (mean difference
3.0 mg/dl, P ¼ 0.06) and triglycerides (mean difference 6.4 mg/dl,
P ¼ 0.0002) among anovulatory cycles when compared with ovulatory
cycles (Fig. 1) with more prominent changes in TC and LDL observed
during the luteal phase. No differences were observed with HDL
(mean difference 20.2 mg/dl, P ¼ 0.8).
To assess the relationship between cholesterol and subsequent
ovulation, we used two different measures of cholesterol: (i) baseline
levels and (ii) four measures preceding ovulation (during menses, mid-
follicular phase, late follicular phase and LH/FSH surge). Baseline lipo-
protein cholesterol levels were not associated with risk of subsequent
anovulation for any of the lipoprotein cholesterol parameters
(Table II). However, we noted a slight increased risk of anovulation
associated with increased levels of TC when multiple measures of
TC up to the time of ovulation were used as the exposure. For
every 5 mg/dl increase in TC, the odds of subsequent anovulation
increased by 1.07 (OR 1.07; 95% CI 0.99–1.15; P ¼ 0.09). To
assess for confounding by indicators of androgen excess, additional
models including LH:FSH ratio, HOMA-IR, insulin, SHBG, hirsutism
score and current acne were created. The results did not differ
(data not shown).
The anovulatory women in our study displayed several character-
istics of endocrine and metabolic disturbances after adjusting for age
and BMI (Table III). Specifically, anovulatory women exhibited higher
LH:FSH ratios (mean difference day 2, 0.26, P ¼ 0.0002) and lower
SHBG levels (mean difference, 29.88 nmol/l, P ¼ 0.0003). In our
assessment of hyperinsulinemia, we observed no differences in
glucose (mean difference, 20.92 mg/dl, P ¼ 0.38) or HOMA-IR
(mean difference, 0.19, P ¼ 0.17); however, insulin levels tended to
Figure 1 Predicted mean lipoprotein cholesterol levels across the menstrual cycle adjusted for age and BMI, by anovulatory status (n ¼ 259). HDL,
high-density lipoprotein; LDL, low-density lipoprotein.
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be higher among women with at least one anovulatory cycle (mean
difference, 1.10 uIU/ml, P ¼ 0.06). Phenotypically, self-reported
hirsutism score assessments based on a modification of the
Ferriman–Gallwey scale with five sites (Ferriman and Gallwey, 1961)
were similar between anovulatory and ovulatory women (mean differ-
ence, 0.13, P ¼ 0.78). The prevalence of acne tended to be higher
among women with at least one anovulatory cycle (mean difference,
15.4, P ¼ 0.08).
Finally, several endocrine and metabolic disturbances were associ-
ated with risk of incident anovulation. In particular, increased
LH:FSH ratios and decreased SHBG levels on Day 2 were predictive
of anovulation in a given cycle. The presence of current acne was
also predictive of anovulation. However, insulin levels, hirsutism
score and HOMA-IR were not predictive of anovulation. ORs and
95% CI reflecting the association between these covariates and the
occurrence of anovulation are displayed in Fig. 2.
All analyses were completed using two classifications for anovula-
tion. Results using the less conservative definition of anovulation
(peak progesterone across the cycle ≤5 ng/ml regardless of LH con-
centration, n ¼ 65) yielded similar results to those presented using the
more conservative definition for anovulation (data not shown).
Discussion
In this prospective cohort of self-reported regularly menstruating
women, we observed poorer lipid profiles during anovulatory cycles;
however, there were no statistically significant associations between
baseline lipoprotein cholesterol levels and risk of incident anovulation.
It does not appear as though higher lipoprotein cholesterol levels
predict anovulation. Although we cannot completely rule out the
steroid hypothesis, the slight increased risk of anovulation associated
with increased levels of TC observed when using multiple measures
of TC raises the possibility of an underlying weak association that may
be detected in a larger study with greater study power, or in women
who are more likely to be anovulatory. The women who experienced
at least one anovulatory cycle displayed several endocrine or metabolic
disturbances. Furthermore, we observed that several of these endo-
crine characteristics—increased Day 2 LH:FSH ratio, presence of
acne and decreased levels of SHBG—were predictive of sporadic ano-
vulatory cycles. These results together suggest that an endocrinologic
disturbance may lead to, or be the result of, sporadic anovulation.
As there is a lack of comparable research on this topic in normal,
healthy women, we compared our results with prior studies of
women diagnosed with ovulatory disorders, such as PCOS (Zawadski
and Dunaif, 1992; Rotterdam, 2004; Azziz et al., 2009). Like our group
of women with anovulatory cycles, despite regular menstrual cycles,
women with PCOS have a poorer lipid profile (Rajkhowa et al.,
1997; Pirwany et al., 2001; Yilmaz et al., 2005; Macut et al., 2008;
Valkenburg et al., 2008; Moran and Teede, 2009; Akram et al.,
2010). However, we did not observe lipid abnormalities as severe
as those often reported for women with a PCOS diagnosis (Macut
et al., 2008). This is likely a consequence of our strict study
inclusion/exclusion criteria which purposefully excluded women at
high risk or diagnosed with PCOS. However, we did not observe
the differences in HDL cholesterol previously reported among
women with a PCOS diagnosis compared with women without a
PCOS diagnosis (Rajkhowa et al., 1997; Yilmaz et al., 2005; Macut
et al., 2008; Valkenburg et al., 2008). This could in part be related
to the fact that full metabolic disturbances may not be present in
women with only sporadic anovulation (Rizzo et al., 2009).
Biologically, an association between lipid levels and ovulation might
be expected because of the role of cholesterol in steroid biosynthesis
(Strauss, 2004). Furthermore, in studies where women with PCOS
were treated with cholesterol-lowering medications, not only did
their cholesterol levels decline, but also their testosterone levels,
LH:FSH levels, and hirsutism scores declined (Duleba et al., 2006;
Banaszewska et al., 2007; Kodaman and Duleba, 2008). The results
of the current study do not rule out the steroid hypothesis; rather,
they suggest that an underlying association may exist (albeit weak),
the detection of which will require greater study power. It is possible
that perhaps the poorer lipid profiles observed among women with
PCOS are a consequence, rather than a cause, of endocrine disturb-
ance and anovulation. The observed associations between lipoprotein
cholesterol levels and anovulation might be explained by changing
androgen levels, for which we unfortunately did not capture data.
Alternatively, the observed associations between lipoprotein choles-
terol levels and anovulation may not be the result of the steroid bio-




Table II Results of inverse probability weighted
generalized linear mixed effects models of the
association between lipoprotein cholesterol levels






cholesterol up to predicted
time of ovulation and
anovulationb
ORc 95% CI P-value OR 95% CI P-value
TC per 5 mg/dl
1.03 (0.95, 1.11) 0.51 1.07 (0.99, 1.15) 0.09
HDL cholesterol per 5 mg/dl
1.01 (0.85, 1.19) 0.92 1.02 (0.86, 1.20) 0.86
LDL cholesterol per 5 mg/dl
1.02 (0.94, 1.11) 0.66 1.05 (0.96, 1.14) 0.28
Triglycerides per 5 mg/dl
1.05 (0.97, 1.13) 0.23 1.04 (0.99, 1.09) 0.16
OR, odds ratio; CI: confidence interval; HDL, high-density lipoprotein cholesterol;
LDL, low-density lipoprotein cholesterol; TC, total cholesterol.
aBaseline levels of lipoprotein cholesterol levels were measured on Day 2 of menses
during the first cycle under study. These models evaluate the association between
baseline lipoprotein cholesterol and anovulation using generalized linear mixed
models.
bLevels of lipoprotein cholesterol were allowed to vary up to the time of predicted
ovulation, and included up to four measurements per woman per cycle. These
models evaluate the association between lipoprotein levels preceding ovulation and
anovulation in that cycle using inverse probability weighted generalized linear mixed
models.
cModel is adjusted for age, age at menarche, BMI, fiber intake and total energy. In
inverse probability weighted models for the association of lipoprotein cholesterol
levels up to the predicted time of ovulation, models also adjusted for levels of other
reproductive hormones that are changing up to the time of predicted ovulation.
Models that only include baseline measurements are assumed to not be affected by
time-varying confounding by other hormones.
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In this study, women with at least one anovulatory cycle demon-
strated higher levels of several non-specific markers for androgen
bioactivity, including higher LH:FSH ratios (Homburg, 2002) and
higher follicular phase LH levels (Balen et al., 1995), all consistent
with, but not diagnostic of, androgen excess. Increased LH:FSH
ratios are indicative of hypothalamic–pituitary–ovarian dysfunction,
characteristic of women with PCOS (Azziz et al., 2009). We also
observed lower SHBG levels among the anovulatory women, likely
secondary to hyperinsulinemia and associated with excess androgen
activity (Pugeat et al., 1996). Insulin levels were increased to a small
.............................................................................................................................................................................................
Table III Markers of endocrine function by ovulatory status.
Overalla Ovulatory Anovulatoryb P-valuec
n 5 259 n 5 224 n 5 35
Hirsutism score 3.03+2.58 3.01+2.58 3.14+2.66 0.78
Currently have acne: n (%)d 72 (30.5) 58 (28.4) 14 (43.8) 0.08
LH:FSH ratio
Day 2 0.61+0.44 0.61 (0.57, 0.65) 0.87 (0.73, 1.02) ,0.01
Day 7 0.71+0.47 0.71 (0.67, 0.75) 0.89 (0.76, 1.03) 0.01
Average of Day 2 and 7 0.70+0.45 0.67 (0.64, 0.71) 0.93 (0.80, 1.07) ,0.01
SHBG (nmol/l): Day 2 44.50+29.05 45.06 (42.54, 47.73) 35.18 (30.33, 40.82) ,0.01
Glucose (mg/dl): Day 2 87.00 + 7.00 87.31 (86.57, 88.05) 86.39 (84.49, 88.30) 0.38
Insulin (uIU/ml): Day 2 6.00 + 4.50 5.79 (5.42, 6.18) 6.89 (5.82, 8.15) 0.06
HOMA-IR: Day 2 1.32 + 0.56 1.29 (1.21, 1.38) 1.48 (1.24, 1.76) 0.17
ANOVA, analysis of variance; CI, confidence interval; HOMA-IR, homeostasis model assessment of insulin resistance; SHBG, sex hormone-binding globulin.
aValues are mean+ SD for overall population. Values for ovulatory and anovulatory women are predicted means (95% CI) after adjusting for age and BMI. LH:FSH ratio, SHBG, Insulin
and HOMA-IR are geometric means.
bAt least one anovulatory cycle. Twenty-eight women in the study had only one anovulatory cycle, and seven women in the study had two anovulatory cycles. There were a total of 42
anovulatory cycles out of a total 509 in the BioCycle Study.
cP-value for continuous variables calculated using ANOVA, for acne calculated using a x2 test.
dAcne: five or more pimples, pustules or nodules on the face (except nose) during the last 3 months.
Figure 2 ORs and 95% CIs for associations between increases in endocrine factors and risk of incident anovulation by cycle, adjusted for TC, age,
age at menarche, BMI, fiber intake and total energy. HOMA-IR, homeostasis model assessment of insulin resistance; SHBG, sex hormone-binding
globulin; TC, total cholesterol.
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degree among anovulatory women, an observation consistent with the
insulin resistance that also frequently accompanies PCOS (Dunaif,
2006). These endocrine parameters were found to be significant pre-
dictors of sporadic anovulation, an apparently reversible condition that
may be more common among certain groups of eumenorrheic
women than originally thought (De Souza et al., 1998). Other investi-
gators, however, suggest that anovulation occurs among eumenor-
rheic women only on a very infrequent basis (Malcolm and
Cumming, 2003; Chatterton et al., 2005). This is the first study, to
our knowledge, to prospectively identify endocrine markers of spora-
dic anovulation in regularly menstruating women.
Our study offers several advantages over previous studies of lipids
and anovulation, in particular the prospective evaluation of the associ-
ation between baseline lipoprotein cholesterol levels and incident ano-
vulation. By preserving temporality, we were able to further evaluate
whether the detected associations were a result of the biological
effects of lipoprotein cholesterol on anovulation, rather than being
symptomatic of an underlying condition leading to both ovulatory dys-
function and a more atherogenic lipid profile. In addition, we were able
to evaluate the possibility of confounding by underlying endocrine dis-
turbances by adjusting for several markers of endocrine function. This
study is further distinguished from previous research by its strict
inclusion/exclusion criteria, which ensured a sample of eumenorrheic
women without a prior clinical diagnosis of PCOS.
While the current study allowed us to expand upon previous
studies in this area, we were limited by several factors. Importantly,
we were unable to directly measure androgen levels, and had to
rely on several non-specific markers to assess androgen activity. In
addition, daily measures of progesterone and transvaginal ultrasounds
(the gold standard) were not available to assess ovulation. However,
multiple well-timed serum hormone measurements (on average, 2,
7 and 13 days before, and 2, 5, 8 and 12 days after the mid-cycle
LH surge), along with the use of fertility monitors measuring LH
daily in urine, were used to aid in classifying ovulatory cycles. We
also employed a conservative definition for anovulation to avoid
potential misclassification. Despite these measures, misclassification
of anovulation is possible. The small number of anovulatory cycles
limits the statistical power available to detect subtle effects, if such
an effect exists.
In conclusion, we detected higher TC (P ¼ 0.01), LDL (P ¼ 0.06)
and triglyceride (P ¼ 0.0002) levels in regularly menstruating women
with anovulatory cycles when multiple measurements across the
cycle were considered; however, baseline lipoprotein cholesterol
levels were not significantly associated with incident anovulation.
Only when multiple measures of TC were included did we observe
a weak and marginally significant association with risk for anovulation.
While these results do not rule out the steroid hypothesis, they do not
support a strong association between lipoprotein cholesterol levels
and anovulation. Regularly menstruating women with at least one ano-
vulatory cycle tended to exhibit endocrine and metabolic disturbances
similar to, but less severe than, women with PCOS. Collectively, these
findings further underscore the possibility of a gradient of severity of
endocrine and metabolic disturbances proportional to the degree of
ovulatory dysfunction. These data are preliminary and more research
is needed to identify the pathophysiology of incident anovulation
among eumenorrheic women, particularly given the absence of
measured androgens here.
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